News
EMA committee recommends approval of AstraZeneca’s fixed-duration Calquence-based regimens for 1st-line chronic lymphocytic leukaemia: Cambridge, UK Wednesday, April 30, 2025, 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback